Total cholesterol and low density lipoprotein (LDL) cholesterol in obstructive sleep apnoea (OSA) Source: Annual Congress 2007 - Metabolic consequences of obstructive sleep apnoea Year: 2007
Relationship between obstructive sleep apnea syndrome (OSAS) and obesity, cholesterol disorders, blood pressure, and anatomical alterations Source: Eur Respir J 2006; 28: Suppl. 50, 817s Year: 2006
Leptin and ghrelin levels in patients with obstructive sleep apnoea: effect of CPAP treatment Source: Eur Respir J 2003; 22: 251-257 Year: 2003
Effect of 8 week CPAP therapy on insulin resistance, serum leptin and lipid concentrations among obstructive sleep apnea hypopnea syndrome (OSAS) patients Source: Eur Respir J 2004; 24: Suppl. 48, 330s Year: 2004
Effects of apolipoprotein E genotype on serum lipids in obstructive sleep apnoea Source: Eur Respir J 2014; 43: 1097-1105 Year: 2014
Metabolic disturbances in patients with obstructive sleep apnoea syndrome Source: Eur Respir Rev 2007; 16: 196-202 Year: 2007
Effects of CETP and APOE polymorphisms on lipoprotein levels in patients with obstructive sleep apnea Source: Annual Congress 2012 - Sleep disorders in internal medicine Year: 2012
Correlation between severity of obstructive sleep apnea (Osa) and serum total cholesterol: Hdl cholesterol (Tc:Hdl) ratio Source: International Congress 2016 – Hypoxia, oxidative stress, and biomarkers in obstructive sleep apnoea Year: 2016
Effect of arterial hypertension, obesity and overnight desaturation on plasma uric acid concentration in obstructive sleep apnoea (OSA) patients Source: Annual Congress 2012 - Physiology, obesity and the downstream effects of OSA Year: 2012
Elevated leptin is associated with impaired glucose tolerance in obstructive sleep apnoea (OSA) Source: Eur Respir J 2006; 28: Suppl. 50, 573s Year: 2006
Impact of obstructive sleep apnoea (OSA) on glucose metabolism Source: Annual Congress 2007 - Cardiovascular and metabolic consequences of obstructive sleep apnoea: early changes, biomarkers and impact of treatment Year: 2007
The influence of 3-weeks‘ therapy of continous positive airway pressure (CPAP) on serum leptin and homocysteine concentration in patients with obstructive sleep apnea (OSA) Source: Annual Congress 2005 - Metabolic control in OSA Year: 2005
Pathogenic role of angiotensin II and oxidised LDL in obstructive sleep apnoea Source: Eur Respir J 2009; 34: 1390-1398 Year: 2009
Effect of continuous positive airway pressure treatment on hypoadiponectinemia in male patients with obstructive sleep apnea syndrome Source: Annual Congress 2005 - Metabolic control in OSA Year: 2005
Reduced plasma fetuin-A levels in patients with obstructive sleep apnoea}, Source: Eur Respir J 2012; 40: 1046-1048 Year: 2012
Plasma adiponectin levels and hypoxic stress in patients with obstructive sleep apnea syndrome (OSAS) Source: Annual Congress 2004 - Systemic and metabolic effects from OSA Year: 2004
Does low plasma adiponectin level affect cardiovasculer risk in obstructive sleep apnea syndrome? Source: Annual Congress 2007 - Metabolic consequences of obstructive sleep apnoea Year: 2007
Endothelial and systemic inflammation in obstructive sleep apnea syndrome: Impact of CPAP therapy on CRP plasma levels Source: Annual Congress 2010 - Biomarkers for oxidative stress, inflammation and cardiovascular function in sleep apnoea Year: 2010
Serum leptin levels in obstructive sleep apnoea patients Source: Annual Congress 2007 - Metabolic consequences of obstructive sleep apnoea Year: 2007
Nocturnal melatonin plasma levels in patients with OSAS: the effect of CPAP Source: Eur Respir J 2007; 30: 496-500 Year: 2007